Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “URIC ACID”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 271 records · Page 15Linked to original sources

Origin and extrarenal elimination of uric acid in man.

The origin of uric acid, metabolic pathways of purine metabolism and the disposition of uric acid in normal man are reviewed. Two thirds of the uric acid is normally excreted through the kidney while one third gains entrance to the gut where it undergoes uricolysis. The pathogenesis of hyperuricemia in primary and secondary gout is discussed. Increased production or decreased excretion of uric acid are the two principal mechanisms of hyperuricemia. The known biochemical defects associated with primary overproduction gout are outlined. Extrarenal uricolysis assumes a greater role when the renal excretion of uric acid is compromised.

Amidophosphoribosyltransferase↗

Acute uric acid nephropathy in pregnancy.

BACKGROUND: Although uric acid clearance increases during gestation, uric acid nephropathy is a rare cause of acute renal failure in the pregnant woman. CASE: A 38-year-old woman experienced acute renal failure due to acute uric acid nephropathy at 30 weeks' gestation. The diagnosis was based on extreme hyperuricemia and an elevated uric acid-creatinine ratio. Treatment with forced diuresis, urine alkalinization, and mannitol infusion resulted in a prompt and complete recovery of renal function. The woman ultimately gave birth to a healthy child. CONCLUSION: Acute uric acid nephropathy during pregnancy responds to conventional medical therapy.

Acute Kidney Injury↗

Effect of urine storage on urinary uric acid concentrations.

Accurate determination of serum and urinary uric acid concentrations is essential for the diagnosis and classification of gout according to uric acid metabolism derangement. Urine and/or serum samples are often kept at either 4 degrees C or -20 degrees C until assayed, when a large number of samples are handled simultaneously. Our preliminary study indicated a significant decrease in urinary uric acid concentration after preservation, regardless of the storage temperature. Uric acid crystals were often observed in these cases which showed a marked decrease in urinary uric acid concentration after storage. In the present study, we sought the factor(s) that might cause this decrease in urinary uric acid concentration, as well as measures to overcome the problem. High urinary uric acid concentration and low pH proved to play major roles in the decrease in urinary uric acid concentration after storage. In contrast, dilution of the urine samples before storage resulted in no significant change in urinary uric acid concentration. Based on these results, we recommend diluting urine before storage for determination of uric acid concentration and avoiding underestimation.

Gout↗

[Serum uric acid--a cardiovasular risk factor?].

Serum uric acid represents an important, independent risk factor for cardiovascular and renal disease in patients with hypertension, heart failure, or diabetes. Elevated serum uric acid is highly predictive of mortality in patients with heart failure or coronary artery disease and of cardiovascular events in patients with diabetes. Although the mechanism(s) by which uric acid may play a pathogenetic role in cardiovascular disease is unclear, hyperuricemia is associated with deleterious effects on endothelial dysfunction, oxidative metabolism, platelet adhesiveness, hemrheology, and aggregation. Whether a reduction in uric acid impacts CV and renal disease remains to be determined. However, recent findings from LIFE in hypertensive patients with LVH suggest the possibility that a treatment-induced decrease in serum uric acid may indeed attenuate cardiovascular risk. Almost one third of the treatment benefit of a losartan-based versus atenolol-based therapy on the composite endpoint (death, myocardial infarction, or stroke) may be ascribed to differences in achieved serum uric acid levels. Clearly, randomized clinical trials are needed to investigate further the long-term cardioprotective benefits issue of reducing hyperuricemia in hypertensive patients.

Angiotensin II Type 1 Receptor Blockers↗

Clinical and biochemical aspects of uric acid overproduction.

Purine nucleotides are synthesized and degraded through a regulated series of reactions which end in the formation of uric acid. Increased uric acid synthesis may be the result of two major pathophysiological disorders: increased de novo purine synthesis and enhanced purine nucleotide degradation, both of which may be the result of an increased or decreased enzyme activity. In addition, some conditions and disorders associated with uric acid overproduction have been recognized as the result of increased ATP degradation or decreased synthesis of ATP. The clinical manifestations of the diseases leading to excess uric acid synthesis are heterogenous, but symptoms related to uric acid overproduction are always secondary to the precipitation of crystals in soft tissues, joints, and the kidney excretory system. In clinical practice, serum urate concentration and urinary uric acid excretion are used to assess uric acid synthesis, taking into account that a purine-rich diet can be a confounding variable. Quantification of uric acid precursors, such as adenosine, inosine, guanosine, hypoxanthine, and xanthine, in biological fluids and intracellular nucleotides has provided further insight into the metabolic disturbances underlying disorders associated with uric acid overproduction. Additional studies are necessary to define precisely the metabolic derangement in idiopathic uric acid overproduction and to assess fully the consequences of increased purine nucleotide degradation, such as free-radical formation, increased adenosine synthesis, and reduced synthesis of signal transducers.

Adenosine Triphosphate↗

[Pharmacological agents affecting uric acid metabolism].

A large number of pharmacological agents affect the serum concentration of uric acid. Some drugs raise serum uric acid level by an increase in uric acid production or a decrease in uric acid excretion, while others lower serum uric acid level by a decrease in uric acid production or an increase in uric acid excretion. In addition, some drugs show so-called biphasic effect; ie, hyperuricemic in lower doses but hypouricemic in higher doses. Hyperuricemic agents contribute to gout and/or urate nephropathy. Among them, pyrazinamide is often used to determine the defective site(s) of uric acid transport in renal tubules in conjunction with uricosuric agents, such as benzbromarone or probenecid. In contrast, the clinical significance of hypouricemic agents other than uricosuric agents has not been emphasized. However, some may induce acute uric acid nephropathy by a significant increase in uric acid excretion. In this review, drugs affecting uric acid metabolism are summarized with regard to their mechanism of action and clinical significance.

Allopurinol↗

Uric acid metabolism in children.

The renal excretion of uric acid in children differs quantitatively, and perhaps qualitatively, from that in adult humans. The younger the child, the greater the renal clearance of uric acid and the greater the excretion of uric acid expressed as mg per kg body weight. During infancy, the reduced ability to maximally concentrate the urine may protect against precipitation of uric acid crystals within the kidney. Conversely, the extremely high urinary uric concentrations places the very small infant at jeopardy during sudden increases in the filtered load of uric acid. Understanding the pharmacologic and physiologic modulators of renal uric acid clearance will allow the pediatrician to minimize the risk of uric acid nephropathy, and to understand the implications of uric acid in the serum or urine in children with fluid and electrolyte disorders. Certainly evaluation of serum and urinary uric acid concentrations is essential in any child with acute renal failure.

Animals↗

Uric acid decomposition in the lower gastrointestinal tract.

Uric acid is the end product of nitrogen metabolism in birds. Despite the very low aqueous solubility of this purine compound, few crystals of uric acid are found in the urine. Instead, uric acid is packaged into small spheres that can pass easily through the duct system of the kidney. After entering the cloaca, these spheres are moved with the urine by antiperistalsis into the rectum and digestive ceca. In the ceca, the uric acid is exposed to a large population of bacteria that can use the uric acid as a metabolic substrate. These bacteria degrade the uric acid to volatile fatty acids (VFA) and ammonia. The VFA are absorbed by the cecal tissue, and the ammonia is incorporated into the production of glutamine. The refluxing of uric acid into the ceca and its subsequent degradation by bacteria provides an effective mechanism for the reclamation of carbon and nitrogen from the urine.

Animals↗

Theophylline interference with the phosphotungstate uric acid test.

The effect of theophylline on serum uric acid measurements was studied. Serum uric acid levels were measured by the phosphotungstate method in eight healthy adults, three of whom received a single u.3-mg/kg oral theophylline dose (as aminophylline elixir) while fasting, and in 15 fasting nonuremic patients (age 14 to 51 years) on chronic oral aminophylline therapy. Uric acid levels also were measured in vitro for serum with known amounts of theophylline (0-49 microgram/ml). Serum theophylline levels were measured by high-pressure liquid chromatography for the patients receiving chronic theophylline therapy and spectrophotometrically for the subjects receiving a single oral dose. In the 15 chronic theophylline patients, actual total serum uric acid levels were not significantly different (p greater than 0.05) from those expected had they been a normal population (i.e., healthy, not receiving theophylline). Likewise, in vitro studies showed no difference in uric acid levels of serum exposed to various concentrations of theophylline. A positive correlation (r greater than or equal to 0.816) between serum theophylline and uric acid levels was found in two of the three single-dose studies, suggesting a pharmacological interaction. Therapeutic serum theophylline levels do not interfere with the measurement of serum uric acid levels by the phosphotungstate method.

Adolescent↗

Clinical and biochemical features of uric acid nephrolithiasis.

A clinical investigation was carried out on patients with uric acid stones in order to study the frequency and pathogenesis of uric acid nephrolithiasis. Of 652 patients with stones in the upper urinary tract in whom the stone composition could be examined, 36 patients and uric acid stones (5.5%). The male to female ratio was 11:1. The average age of the 33 male subjects was 49 +/- 11 years (mean +/- SD), and the 3 females were 22, 37 and 42 years old, respectively. Two of the females showed hypouricemia. With regard to stone composition, pure uric acid stones were present in 26 cases (72%), a mixed uric acid and calcium oxalate stones were found in 6 cases (17%), both pure uric acid and mixed uric acid and calcium oxalate stones were observed in 3 cases (8%), and a mixed uric acid and sodium acid urate stone in 1 (3%). Biochemical studies on male patients showed that the blood uric acid level was higher in the uric acid stone group and the pure uric acid stone group compared to the calcium stone group. The blood uric acid levels of the former 2 groups did not differ from the control group. With respect to urine chemistry, the excretion of calcium in the uric acid stone group was significantly lower than that in the control group. In the uric acid stone group and the pure uric acid stone group the excretion of calcium tended to be lower than that in the calcium stone group. The amounts of oxalic acid excreted in the uric acid stone group and in the pure uric acid stone group were low compared to the calcium stone group. Oxalic acid elimination in these 2 groups did not differ from the control group.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Structure of uric acid concretion developed around a catheter.

A uric acid concretion formed round a catheter (JJ stent) in the bladder and removed intact from the body together with the catheter was studied using an electron scanning microscope. The concretion was composed of anhydrous uric acid, some uric acid dihydrate (< 5 wt.%) and individual particles of calcium oxalate monohydrate. The stone interior was porous with frequent occurrence of differently sized cavities that were either empty or partially filled with particles of uric acid and/or calcium oxalate monohydrate. Calcium oxalate particles were not of crystalluria origin but developed in the cavity. The succession of processes leading to the stone formation was deduced from its inner structure. The stone was formed due to a crystalline growth with minor, if any, participation of sedimentation. The estimated average rate of the calculus development, 2 x 10(-9) m/s, confirms the predominant role of crystalline growth in stone formation and indicates a relatively low urinary supersaturation with respect to uric acid prevailing during the period of calculogenesis.

Calcium Oxalate↗

Effect of morphine on striatal dopamine metabolism and ascorbic and uric acid release in freely moving rats.

Recent ex vivo findings have shown that morphine increases dopamine (DA) and xanthine oxidative metabolism and ascorbic acid (AA) oxidation in the rat striatum. In the present study, we evaluated the effects of subcutaneous daily morphine (20 mg/kg) administration on DA, dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), AA and uric acid in the striatum of freely moving rats using microdialysis. Dialysates were assayed by high performance liquid chromatography with electrochemical detection. On the first day, morphine administration caused a significant increase in extracellular DA, DOPAC, HVA, AA and uric acid concentrations over a 3 h period after morphine. In all treated rats (n = 7), individual concentrations of DOPAC + HVA were directly correlated with individual AA and uric acid concentrations. Last morphine administration on the 4th day increased DOPAC, HVA, AA and uric acid concentrations but failed to increase those of DA. Individual DOPAC + HVA concentrations were still directly correlated with individual AA and uric acid concentrations. These results suggest that systemic morphine increases both striatal DA release and DA and xanthine oxidative metabolism. Only the former effect undergoes tolerance. The increase in DA oxidative metabolism is highly correlated with that of xanthine. The subsequent enhancement in reactive oxygen species production may account for the increase in extracellular AA.

3,4-Dihydroxyphenylacetic Acid↗

The organic matrix of urinary uric acid crystals.

We have demonstrated that urinary uric acid crystals contain an organic matrix within the crystalline boundaries, morphologically similar to that of uric acid stones. Among several glycosaminoglycans in urine, heparan sulfate was almost exclusively identified in this matrix, as in that of uric acid stones. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) showed that several proteins in urine were incorporated in this matrix on a selective basis; two of which were albumin and Tamm-Horsfall mucoprotein. An affinity of uric acid or urate for selective urinary macromolecules in a liquid phase was supposed to be the origin of this matrix. But the proteins in the uric acid stone matrix were not separated by SDS-PAGE. Therefore we could not conclude whether the organic matrix of urinary uric acid crystals is similar to that of uric acid stones.

Crystallization↗

Ontogeny of renal uric acid excretion in the mongrel puppy.

Renal uric acid excretion was examined in 35 mongrel puppies at 1, 30, 60 and 90 days of age and in seven mature mongrel dogs. Uric acid concentrations in plasma and urine were determined using a uricase fluorometric method. Clearance of inulin increased with postnatal age; however, fractional excretion of uric acid (FEUA) decreased from 83% at birth to 51% at 90 days of age (r = -0.675, P less than 0.001). Filtered uric acid and net reabsorption of uric acid increased with postnatal development. The decline in FEUA with postnatal age was unrelated to binding of uric acid to plasma proteins or to urine flow rate. A direct correlation was observed between clearance of uric acid (CUA) and clearance of sodium (CNa) during early development (r = 0.48, P less than 0.001). These data indicate that postnatal maturational patterns of renal urate excretion in mongrel puppies are similar to human newborns.

Age Factors↗

Renal uric acid clearance in human neonates.

Renal clearance of uric acid was examined in 40 premature and term infants during the first 24 hours of life. Creatinine clearance and uric acid clearance increased with increasing gestational age. Serum uric acid concentration (r = -0.31, P less than 0.05) and fractional excretion of uric acid (r = -0.50, P less than 0.01) were inversely related to gestational age; FEUA was nearly 70% at 29 to 31 weeks gestational age, and decreased to a mean value of 39 +/- 14% (+/- SD) at 38 to 40 weeks gestational age. The decline in FEUA with advancing gestational age appears to represent alterations in net renal tubular transport of uric acid, because the filtered load of uric acid increased with gestational age. Postnatal clearance studies were performed in 18 premature infants of 29 to 35 weeks gestational age; FEUA also declined during early postnatal development (r = -0.44, P less than 0.01). In all studies, a relationship between FEUA and fractional excretion of sodium was observed. The high basal excretion of uric acid in infants may increase the risk of acute uric acid nephropathy when excretion demands are increased.

Female↗

The stability of uric acid in ammonium hydroxide.

We examined the stability of uric acid in dilute aqueous ammonium hydroxide solution by mass spectrometry. Uric acid decomposes in ammonium hydroxide even as dilute as 15 mmol/L when the mole ratio of ammonium hydroxide to uric acid is 50:1. There are at least four products of the decomposition, two of which have been identified as allantoin and urea. The slope of the decomposition curve indicates that uric acid is destroyed at an initial rate of 2-3% per hour. In ammonium hydroxide at a concentration of 1 mmol/L and a mole ratio of ammonium hydroxide to uric acid of less than or equal to 3.4, uric acid is not detectably decomposed. Evidently, any method for determination of uric acid that involves treating the analyte with ammonium hydroxide before analysis may destroy it. Therefore, a published method described as being "definitive" for uric acid (J Clin Chem Clin Biochem 1985; 23:129-35) could produce incorrect results because it involves storing the uric acid in 15 mmol/L ammonium hydroxide at a mole ratio of ammonium hydroxide to uric acid of greater than 120:1.

Ammonium Hydroxide↗